BACKGROUND:Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour necrosis factor alpha (TNFalpha) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent. METHODS: Data from a double-blind placebo controlled study of onercept in 126 patients with psoriatic arthritis (PsA) and from pre- and post-adalimumab treatment in 171 patients with rheumatoid arthritis (RA) were used to examine the effect of TNFalpha blockade therapy on adiponectin. RESULTS: Despite expected associations of adiponectin with gender and baseline high-density lipoprotein cholesterol and triglyceride, adiponectin levels did not change over time with TNFalpha blockade therapy in either group. The mean+/-SD absolute change in adiponectin levels was -0.23+/-4.6 microg/ml in patients with PsA treated with combined onercept 50 mg and onercept 100 mg (vs placebo, p=0.60) and 0.28+/-3.23 microg/ml in patients with RA treated with adalimumab (vs baseline, p=0.66). CONCLUSION: These results do not support a significant effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease.
RCT Entities:
BACKGROUND:Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour necrosis factor alpha (TNFalpha) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent. METHODS: Data from a double-blind placebo controlled study of onercept in 126 patients with psoriatic arthritis (PsA) and from pre- and post-adalimumab treatment in 171 patients with rheumatoid arthritis (RA) were used to examine the effect of TNFalpha blockade therapy on adiponectin. RESULTS: Despite expected associations of adiponectin with gender and baseline high-density lipoprotein cholesterol and triglyceride, adiponectin levels did not change over time with TNFalpha blockade therapy in either group. The mean+/-SD absolute change in adiponectin levels was -0.23+/-4.6 microg/ml in patients with PsA treated with combined onercept 50 mg and onercept 100 mg (vs placebo, p=0.60) and 0.28+/-3.23 microg/ml in patients with RA treated with adalimumab (vs baseline, p=0.66). CONCLUSION: These results do not support a significant effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease.
Authors: R Klaasen; M M J Herenius; C A Wijbrandts; W de Jager; L H van Tuyl; M T Nurmohamed; B J Prakken; D M Gerlag; P P Tak Journal: Ann Rheum Dis Date: 2012-03-22 Impact factor: 19.103
Authors: Patrick H Dessein; Angela J Woodiwiss; Gavin R Norton; Linda Tsang; Ahmed Solomon Journal: Arthritis Res Ther Date: 2013-09-20 Impact factor: 5.156
Authors: Rita Polito; Ersilia Nigro; Antonietta Messina; Maria L Monaco; Vincenzo Monda; Olga Scudiero; Giuseppe Cibelli; Anna Valenzano; Elisabetta Picciocchi; Christian Zammit; Daniela Pisanelli; Marcellino Monda; Ivan R Cincione; Aurora Daniele; Giovanni Messina Journal: Front Physiol Date: 2018-07-24 Impact factor: 4.566